Acquired Company
TuHURA Biosciences completed its merger with Kintara Therapeutics on October 17, 2024, with the combined company operating as TuHURA Biosciences, Inc. and trading on Nasdaq under the ticker HURA.
Kintara Therapeutics, Inc. operates as a clinical and commercial stage drug development company with a focus on the treatment of cancer. The Company focuses on identifying clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications. Kintara Therapeutics serves customers worldwide. Show more
Location: 12707 High Bluff Drive, Suite 200, California, 92130, US | Website: www.kintara.com | Industry: Polish and Other Sanitation Good Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$0.72
Open
$0.76
Volume
345,558
Day Range
$0.70 - $0.76
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.12%
Institutional Own.
1.47%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
REM-001 Details Metastatic breast cancer, Cancer | Phase 2/3 Data readout | |
IFX-Hu2.0 Details Cancer, Metastatic merkel cell carcinoma, Cutaneous squamous cell carcinoma | Phase 1b Update | |
VAL-083 Details Glioblastoma, Cancer | Failed Discontinued |